The ‘Ozempic Effect’ on Wall Street Has Gone Overboard

America leads developed nations when it comes to obesity. Those paying close attention to the stock market and recent corporate earnings calls might be forgiven for thinking the problem has been solved.

Call it the Ozempic effect. A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led to fanciful assumptions on Wall Street that spell doom for companies that have profited from America’s obesity problem. It has also led to speculation that gigantic opportunities await those that would benefit from the aggregate weight loss.